CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells

Oncogene

Volumn 29, Issue 47, 2010, Pages 6257-6266

  Chen, K F ^a   Liu, C Y ^b,c   Lin, Y C ^d   Yu, H C ^a   Liu, T H ^a   Hou, D R ^e   Chen, P J ^a   Cheng, A L ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^e NATIONAL CENTRAL UNIVERSITY   (Taiwan)

Author keywords

apoptosis; bortezomib; CIP2A; HCC; PP2A; proteasome inhibitor

Indexed keywords

BORTEZOMIB; PHOSPHOPROTEIN PHOSPHATASE 2A; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; ENZYME INHIBITION; GENE EXPRESSION; GENE SILENCING; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TIMED DRUG RELEASE; UPREGULATION;

ANIMALS; APOPTOSIS; AUTOANTIGENS; BORONIC ACIDS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MEMBRANE PROTEINS; MICE; MICE, NUDE; PHOSPHOPROTEINS; PROTEIN PHOSPHATASE 2; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZINES; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78649511007     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.357     Document Type: Article

References (24)

1. Bielinski VA, Mumby MC. (2007). Functional analysis of the PP2A subfamily of protein phosphatases in regulating Drosophila S6 kinase. Exp Cell Res 313: 3117-3126.
2. Chen KF, Yeh PY, Hsu C, Hsu CH, Lu YS, Hsieh HP et al. (2009a). Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 284: 11121-11133.
3. Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL. (2008). Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 68: 6698-6707.
4. Chen KF, Yu HC, Liu TH, Lee SS, Chen PJ, Cheng AL. (2009b). Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactiva-tion. J Hepatol 52: 88-95.
5. Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X et al. (2009). CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 15: 5092-5100.
6. Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE et al. (2004). Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol 22: 115-119.
7. Gao T, Furnari F, Newton AC. (2005). PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 18: 13-24.
8. Janssens V, Goris J. (2001). Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 353: 417-439.
9. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T et al. (2007). CIP2A inhibits PP2A in human malignancies. Cell 130: 51-62.
10. Khanna A, Bockelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M et al. (2009). MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst 101: 793-805.
11. Li W, Ge Z, Liu C, Liu Z, Bjorkholm M, Jia J et al. (2008). CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res 14: 3722-3728.
12. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al. (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
13. McConkey DJ, Zhu K. (2008). Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 11: 164-179.
14. Mumby M. (2007). PP2A: unveiling a reluctant tumor suppressor. Cell 130: 21-24.
15. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S et al. (2005). The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ ABL-regulated SET protein. Cancer Cell 8: 355-368.
16. Nikiforov MA, Riblett M, Tang WH, Gratchouck V, Zhuang D, Fernandez Y et al. (2007). Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc Natl Acad Sci USA 104: 19488-19493.
17. Ocio EM, Mateos MV, Maiso P, Pandiella A, San-Miguel JF. (2008). New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol 9: 1157-1165.
18. Orlowski RZ, Baldwin Jr AS. (2002). NF-kappaB as a therapeutic target in cancer. Trends Mol Med 8: 385-389.
19. Orlowski RZ, Kuhn DJ. (2008). Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14: 1649-1657.
20. Richardson P, Wolf J, Jakubowiak A, Zonder J, Lonial S, Irwin DH et al. (2008). Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401)+Bortezomib in patients with relapsed or relapsed/ refractory multiple myeloma who were previously relapsed from or refractory to bortezomib. ASH Annual Meeting Abstracts 112: 870-87.
21. 0 auto-antigen of p62 overexpressed in cancer. Oncogene 21: 5006-5015.
22. Verslype C, Van Cutsem E, Dicato M, Arber N, Berlin JD, Cunningham D et al. (2009). The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol 20(Suppl 7): vii1-vii6.
23. Voorhees PM, Orlowski RZ. (2006). The proteasome and protea-some inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 46: 189-213.
24. Yu C, Friday BB, Lai JP, Yang L, Sarkaria J, Kay NE et al. (2006). Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol Cancer Ther 5: 2378-2387.